Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Mallinckrodt
McKesson
McKinsey

Last Updated: June 27, 2022

PERSERIS KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Perseris Kit, and what generic alternatives are available?

Perseris Kit is a drug marketed by Indivior Inc and is included in one NDA. There are nine patents protecting this drug.

This drug has thirty-eight patent family members in seventeen countries.

The generic ingredient in PERSERIS KIT is risperidone. There are thirty drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the risperidone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Perseris Kit

A generic version of PERSERIS KIT was approved as risperidone by APOTEX INC on September 15th, 2008.

  Try it Free

Drug patent expirations by year for PERSERIS KIT
Recent Clinical Trials for PERSERIS KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Indivior Inc.Phase 4

See all PERSERIS KIT clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for PERSERIS KIT

US Patents and Regulatory Information for PERSERIS KIT

PERSERIS KIT is protected by nine US patents.

Patents protecting PERSERIS KIT

Sustained delivery formulations of risperidone compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sustained release small molecule drug formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ADMINISTRATION OF RISPERIDONE

Sustained delivery formulations of risperidone compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING SCHIZOPHRENIA

Sustained release small molecule drug formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING SCHIZOPHRENIA

Sustained delivery formulations of risperidone compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATING SCHIZOPHRENIA

Sustained release small molecule drug formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATING SCHIZOPHRENIA

Sustained delivery formulations of risperidone compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sustained delivery formulations of risperidone compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SCHIZOPHRENIA

Sustained release small molecule drug formulation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Indivior Inc PERSERIS KIT risperidone FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 210655-001 Jul 27, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Indivior Inc PERSERIS KIT risperidone FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 210655-002 Jul 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Indivior Inc PERSERIS KIT risperidone FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 210655-001 Jul 27, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Indivior Inc PERSERIS KIT risperidone FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 210655-001 Jul 27, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Indivior Inc PERSERIS KIT risperidone FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 210655-002 Jul 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Indivior Inc PERSERIS KIT risperidone FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 210655-001 Jul 27, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for PERSERIS KIT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Laboratorios Farmacéuticos Rovi, S.A. Okedi risperidone EMEA/H/C/005406
Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
Authorised no no no 2022-02-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for PERSERIS KIT

See the table below for patents covering PERSERIS KIT around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1940351 FORMULATION DE MEDICAMENTS A PETITES MOLECULES A LIBERATION PROLONGEE (SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION) See Plans and Pricing
Israel 190499 פורמולציה לשחרור מושהה של ריספרידון הניתנת להזרקה (Injectable sustained release risperidone formulation) See Plans and Pricing
Argentina 056554 FORMULACION DE FARMACO DE MOLECULA PEQUENA DE LIBERACION SOSTENIDA See Plans and Pricing
Hong Kong 1143731 利培酮類化合物的緩釋製劑 (SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUNDS) See Plans and Pricing
Spain 2385384 See Plans and Pricing
Poland 2361609 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PERSERIS KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0196132 94C0008 Belgium See Plans and Pricing PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
AstraZeneca
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.